| Dr Steven D Williams, MD | |
|
300 Riverside Dr., Suite 2500, Bourbonnais, IL 60914-4996 | |
| (815) 939-7141 | |
| (815) 937-1670 |
| Full Name | Dr Steven D Williams |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 39 Years |
| Location | 300 Riverside Dr., Bourbonnais, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255426169 | NPI | - | NPPES |
| 036075799 | Medicaid | IL | |
| 36075799 | Medicaid | IL | |
| 4632039 | Other | IL | BC GROUP # |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverside Medical Center | Kankakee, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Riverside Health System | 3274434717 | 152 |
News Archive
Reconfigured body after reconfigured body, the hands of Alexander Moya, M.D., Director of the Center for Weight Loss Body Contouring and Assistant Director of the Geisinger Center for Aesthetics and Cosmetic Surgery at Geisinger Medical Center (GMC), skillfully addresses the excess skin his patients contend with following the loss of dozens, if not often hundreds, of pounds. According to Dr. Moya, it's this final therapeutic step of removing this skin and reshaping their bodies that often puts weight-loss patients at peace with themselves and what they see in the mirror every morning.
C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius™ MRI Marker. The novel Positive-Signal MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance imaging procedure.
Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).
A recent paper available on the preprint server bioRxiv* reports preliminary data on the ability of low molecular weight heparins to interact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), elicit structural changes in its key proteins and subsequently halt cell invasion.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version for Bayer Healthcare Pharmaceuticals' oral contraceptive Yaz® (Drospirenone and Ethinyl Estradiol) Tablets.
› Verified 3 days ago
| Entity Name | Riverside Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417061193 PECOS PAC ID: 3274434717 Enrollment ID: O20040116000780 |
News Archive
Reconfigured body after reconfigured body, the hands of Alexander Moya, M.D., Director of the Center for Weight Loss Body Contouring and Assistant Director of the Geisinger Center for Aesthetics and Cosmetic Surgery at Geisinger Medical Center (GMC), skillfully addresses the excess skin his patients contend with following the loss of dozens, if not often hundreds, of pounds. According to Dr. Moya, it's this final therapeutic step of removing this skin and reshaping their bodies that often puts weight-loss patients at peace with themselves and what they see in the mirror every morning.
C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius™ MRI Marker. The novel Positive-Signal MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance imaging procedure.
Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).
A recent paper available on the preprint server bioRxiv* reports preliminary data on the ability of low molecular weight heparins to interact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), elicit structural changes in its key proteins and subsequently halt cell invasion.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version for Bayer Healthcare Pharmaceuticals' oral contraceptive Yaz® (Drospirenone and Ethinyl Estradiol) Tablets.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven D Williams, MD Po Box 781, Kankakee, IL 60901-0781 Ph: (815) 935-7538 | Dr Steven D Williams, MD 300 Riverside Dr., Suite 2500, Bourbonnais, IL 60914-4996 Ph: (815) 939-7141 |
News Archive
Reconfigured body after reconfigured body, the hands of Alexander Moya, M.D., Director of the Center for Weight Loss Body Contouring and Assistant Director of the Geisinger Center for Aesthetics and Cosmetic Surgery at Geisinger Medical Center (GMC), skillfully addresses the excess skin his patients contend with following the loss of dozens, if not often hundreds, of pounds. According to Dr. Moya, it's this final therapeutic step of removing this skin and reshaping their bodies that often puts weight-loss patients at peace with themselves and what they see in the mirror every morning.
C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius™ MRI Marker. The novel Positive-Signal MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance imaging procedure.
Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).
A recent paper available on the preprint server bioRxiv* reports preliminary data on the ability of low molecular weight heparins to interact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), elicit structural changes in its key proteins and subsequently halt cell invasion.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version for Bayer Healthcare Pharmaceuticals' oral contraceptive Yaz® (Drospirenone and Ethinyl Estradiol) Tablets.
› Verified 3 days ago
Dr. Giovanni M Salerno, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 461 Brown Blvd, Bourbonnais, IL 60914 Phone: 715-933-7900 Fax: 815-933-7090 |